Literature DB >> 16518477

[Molecular biology of CLL].

Agota Szepesi1.   

Abstract

Recently, major advances have occurred in our understanding of the biology of chronic lymphocytic leukemia (CLL). CD5-positive CLL cells were once assumed to originate from immature, immunologically incompetent B lymphocytes, and to passively accumulate due to increased life time. In 1999, two research groups demonstrated that CLL, which is a morphologically uniform but clinically heterogenous disease, can be classified into two major subgroups on the basis of the mutational status of the immunoglobulin heavy chain (IgH) genes. It was also suggested that these two groups both originate from mature cells that have passed the antigen selection process. This hypothesis was confirmed by gene expression studies indicating a uniform pattern characteristic to memory cells, as well as specific B-cell receptor (BCR) structures supporting the existence of a functional antigen selection. The differences in the BCR signal transduction mechanisms may underlie the different clinical behavior in which zeta-associated tyrosine kinase (ZAP-70) may play a pivotal role, since elevated ZAP-70 expression is likely to be an unfavorable prognostic factor in CLL. The diagnostic testing for ZAP-70 expression plays an important role in the therapeutic decisions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518477     DOI: HUON.2005.49.4.0327

Source DB:  PubMed          Journal:  Magy Onkol        ISSN: 0025-0244


  2 in total

1.  Exonal switch down-regulates the expression of CD5 on blasts of acute T cell leukaemia.

Authors:  A K Rai; A Singh; A Saxena; T Seth; V Raina; D K Mitra
Journal:  Clin Exp Immunol       Date:  2017-09-05       Impact factor: 4.330

2.  Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria.

Authors:  Anazoeze Jude Madu; Kaladada Korubo; Augustine Okoye; Ifeoma Ajuba; Augustine N Duru; Angela O Ugwu; Oji Nnachi; Helen Chioma Okoye
Journal:  Malawi Med J       Date:  2019-06       Impact factor: 0.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.